Bone Marrow Transplant Clinical Trial - Rafael Pharmaceuticals Inc. AML003


Open (Study open and enrolling)


 CONDITION(S): Relapsed/Refractory Acute Myeloid Leukemia - TRIAL: Rafael Pharmaceuticals Inc. AML003 - Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML    

A Phase III study to evaluate the safety and efficacy of CPI-613® (devimistat) in combination with High Dose Cytarabine and Mitoxantrone in comparison with high dose Cytarabine and Mitoxantrone in older patients with relapsed/refractory Acute Myeloid Leukemia. CPI-613® (devimistat) targets the altered energy metabolism and processes for production of ATP and essential bio-intermediates unique to and characteristic of most cancer cell types. The addition of CPI-613® (devimistat) to high dose cytarabine and mitoxantrone (CHAM) will improve the complete remission (CR) rate in patients 50 years or older with relapsed or refractory AML when compared to HAM alone.


CPI-613 + High Dose Cytarabine and MitoxantroneDrug: High Dose Cytarabine and Mitoxantrone

Trial Type



Phase 3


Relapsed/Refractory Acute Myeloid Leukemia


Rafael Pharmaceuticals Inc. AML003